title: Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization.
abstract: BACKGROUND
  Photodynamic therapy is a relatively new modality for the treatment of subfoveal choroidal neovascularization (CNV). An unusual response to verteporfin therapy of myopic CNVs is reported.
  
  
  METHODS
  Out of 187 CNVs secondary to pathologic myopia treated with photodynamic therapy, three eyes manifested two separate foci of CNV before treatment. The three eyes were treated with verteporfin therapy according to the standard protocol, using a single spot of light that covered both neovascular fronds.
  
  
  RESULTS
  All the three eyes showed neovascular bridging of the two separate neovascular complexes 1 month after treatment.
  
  
  CONCLUSIONS
  Eyes with multiple foci of myopic CNV may show unexpected outcomes after verteporfin therapy. Several factors, such as changes of the retinal pigment epithelium and choroidal vasculature involved in the treatment and enhanced expression of vascular endothelial growth factor, may play a role.
authors.affiliation: Department of Ophthalmology, University of Udine, Piazzale S. Maria della Misericordia, 33100, Udine Italy. paolo.lanzetta@uniud.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Lanzetta
authors.forename: Maurizio Battaglia
authors.initials: MB
authors.lastname: Parodi
authors.forename: Massimo
authors.initials: M
authors.lastname: Ambesi-Impiombato
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ravalico
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D003286:Contracture / Q000209:etiology* / Q000473:pathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011183:Postoperative Complications; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin